The company  does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. The compound is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Fareva today announced an agreement regarding the fill & finish manufacturing of CureVac´s COVID-19 vaccine candidate, CVnCoV, at Fareva’s Pau and Val-de-Reuil-sites in France. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. Copy and paste multiple symbols separated by commas. It is headquartered in Tübingen, Germany, and employs more than 500 people at … CureVac began development of its mRNA-based COVID-19 vaccine candidate in January 2020. CureVac had 43.4 million euros (around $51 million) as of March 31, 2020. node.dataset.value : node.getAttribute('data-value'); if (selectedValue) { for (var j = 0; j < node.options.length; j++) { if(node.options[j].value === selectedValue) { node.options[j].selected = 'selected';break;}}}}}, Nasdaq Boardvantage Board Portal Software, Do Not Sell My Personal Information (CA Residents Only). Dec 14, 2020 1:27AM EST Credit: REUTERS/Andreas Gebert BERLIN, Dec 14 (Reuters) - Germany's CureVac CVAC.O announced on Monday that it … Real time CureVac (CVAC) stock price quote, stock graph, news & analysis. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. CureVac had its initial public offering on the New York Nasdaq in August 2020. T +49 7071 9883-1298 These 3 Dirt-Cheap Stocks Have PE Ratios Under 12, 3 Bubble Stocks Robinhood Investors Keep Chasing, var dom1 = document.querySelector('#form1783 #field1');var field1 = new LiveValidation(dom1, {validMessage: "", onlyOnBlur: false, wait: 300});field1.add(Validate.Presence, {failureMessage:"This field is required"});field1.add(Validate.Format, {pattern: /(^[A-Z0-9!#$%&'\*\+\-\/=\?\^_`\{\|\}~][A-Z0-9!#$%&'\*\+\-\/=\?\^_`\{\|\}~\.]{0,62}@(([A-Z0-9](?:[A-Z0-9\-]{0,61}[A-Z0-9])?)(\.[A-Z0-9](?:[A-Z0-9\-]{0,61}[A-Z0-9])? When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. By Thomas Niel Sep 3, 2020, 3:29 pm EST September 3, 2020 Pandemic vaccine plays have cooled off as of late. CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. It is dedicated to the sterile fill & finish manufacturing of biologics and high potent APIs, including freeze-dried products. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. ET. CureVac had its initial public offering on the New York Nasdaq in August 2020. In June 2020, the German Federal Ministry of Economics and Energy announced its commitment to invest 300 million Euros in CureVac through the Kreditanstalt für Wiederaufbau (KfW). “We are pleased to partner with Fareva for the fill & finish manufacturing of our COVID-19 vaccine candidate in France,” added Dr. Florian von der Mülbe, Chief Production Officer of CureVac. This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the “company”) regarding future events or future results, in contrast with statements that reflect historical facts. An employee of German biopharmaceutical company CureVac, demonstrates research on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. (RTTNews) - CureVac N.V. (CVAC) shares are down more than 8 percent on Thursday morning trade continuing its fall since December 7 as it is a … By Chris Lau, InvestorPlace Contributor Sep 2, 2020, 11:50 am EST September 2, 2020 Since its IPO in mid-August, CureVac N.V. (NASDAQ: CVAC ) is taking investors on a wild ride. CureVac and Fareva Sign Agreement For Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV - joint press release. “We are proud to contribute to the fill & finish manufacturing of this innovative vaccine candidate from CureVac. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Further information can be found at www.curevac.com. CureVac had its initial public offering on the New York Nasdaq in August 2020. (RTTNews) - CureVac N.V. (CVAC) shares are declining on Friday morning trade, as the company is expecting results for its efficacy studies by first half of … Buying CureVac stock could produce a 27.5% annual compounded return over the next two years. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. CureVac had its initial public offering on the New York Nasdaq in August 2020. The compound is an optimized, non-chemically modified mRNA, encoding the pre-fusion stabilized full-length spike protein of the SARS-CoV-2 virus. And that includes recent IPO CureVac (NASDAQ: CVAC ). Location*Please select…United StatesAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, the Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, the former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia, Federated States ofMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian Territory, OccupiedPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet NamVirgin Islands (British)Virgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe. The forward-looking statements included in this press release are made only as of the date hereof. Adding to the attraction, Hanes has kept up its regular stock dividend, maintaining the payout at 15 cents per common share, for all of 2020. Franz-Werner Haas, CEO of biopharmaceutical company CureVac, is seen in front of the company's headquarters in Tuebingen, southern Germany December 15, 2020. — AFP pic FRANKFURT, Dec 17 — CureVac CEO Franz-Werner Haas readily admits his German biotech firm is “a bit behind” in the Covid-19 vaccine race, despite using the same cutting-edge technology as rivals Moderna and … The mRNA vaccine will be supplied to Fareva by CureVac. CureVac plans to initiate the pivotal Phase 2b/3 clinical study before end of 2020. The data support CureVac’s decision to advance a 12µg dose in its upcoming pivotal Phase 2b/3 study, which CureVac plans to initiate before the end of 2020. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? This agreement confirms Fareva’s strategy of investing significantly in the areas of sterile manufacturing, enlarging our technology offering,” said Alexandre Bastit, Vice President of EMEA Pharma Sales at Fareva. On Monday, the company has announced the enrollment of the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. Palantir’s Covid-19 Contract With US Government Under Threat – Report, Weekly Preview: Earnings To Watch This Week (IBM, INTC, NFLX, UAL), What To Do if You Haven't Received Your $600 Stimulus Check, In The Money: The Pandemic, Consumer Confidence, And Debt [Recorded 1/20/21], German Green Chief Hails Biden's Planned Return to Paris Accord, #TradeTalks: A form of volatility control that monitors and reacts intraday to market volatility, WEF Sees Disease, Climate as Top Global Risks for 2021, These Nasdaq Biotech Stocks Doubled in 2020. Iata raspunsul specialistului! These symbols will be available throughout the site during your session. The compound is an optimized, non-chemically modified mRNA, encoding the pre-fusion stabilized full-length spike protein of the SARS-CoV-2 virus. )+[a-z]{2,63}/i);}, failureMessage: "Value must not contain any URL's"});field5.add(Validate.Presence, {failureMessage:"This field is required"});field5.add(Validate.Length, {tooShortMessage:"Invalid length for field value", tooLongMessage: "Invalid length for field value", minimum: 4, maximum: 4});function handleFormSubmit(ele) { var submitButton = ele.querySelector('input[type=submit]'); var spinner = document.createElement('span'); spinner.setAttribute('class', 'loader'); submitButton.setAttribute('disabled', true); submitButton.style.cursor = 'wait'; submitButton.parentNode.appendChild(spinner); return true; }function resetSubmitButton(e){ var submitButtons = e.target.form.getElementsByClassName('submit-button'); for(var i=0;i